VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Pinter-Brown on CTCL Combination Therapies

Lauren Pinter-Brown, MD
Published: Wednesday, Mar 13, 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma (CTCL).

Combination therapies in CTCL have not been studied a great deal. There is a desire for many practicing physicians to "layer" treatments that only garner some response to prevent the disease from breaking loose, Pinter-Brown says. As a result, patients are often treated with combinations that have not been studied. There are some combination therapies that have been studied: retinoids with light, interferon with light, photopheresis with interferon, and photopheresis with retinioids.

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma (CTCL).

Combination therapies in CTCL have not been studied a great deal. There is a desire for many practicing physicians to "layer" treatments that only garner some response to prevent the disease from breaking loose, Pinter-Brown says. As a result, patients are often treated with combinations that have not been studied. There are some combination therapies that have been studied: retinoids with light, interferon with light, photopheresis with interferon, and photopheresis with retinioids.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x